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Pancreatic ductal adenocarcinomaWe demonstrated that increasing intracellular cAMP concentrations result in the inhibition of migration of
PANC-1 and other pancreatic ductal adenocarcinoma (PDAC) cell types. The rise of cAMP was accompanied
by rapid and reversible cessation of rufﬂing, by inhibition of focal adhesion turnover and by prominent loss
of paxillin from focal adhesions. All these phenomena develop rapidly suggesting that cAMP effectors have
a direct inﬂuence on the cellular migratory apparatus. The role of two primary cAMP effectors, exchange protein
activated by cAMP (EPAC) and protein kinase A (PKA), in cAMP-mediated inhibition of PDAC cell migration and
migration-associatedprocesseswas investigated. Experimentswith selective activators of EPAC and PKAdemon-
strated that the inhibitory effect of cAMP onmigration, rufﬂing, focal adhesion dynamics and paxillin localisation
is mediated by PKA, whilst EPAC potentiates migration.
© 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.1. Introduction
Pancreatic ductal adenocarcinoma (PDAC), a leading cause of
cancer-related deaths world-wide, is characterised by widely dissemi-
nated metastatic disease at diagnosis. As a consequence most patients
die within one year, and less than 5% of patients survive ﬁve years
[37]. Global genomic analyses of individual pancreatic tumours and
corresponding metastases have recently provided novel insights into
the molecular characteristics of PDAC [4,42]. Moreover, it was recently
demonstrated that early precursor cells, previously thought to lack
invasive properties, appeared capable of invading and seeding distant
sites [34,40]. Nonetheless, despite advances in our understanding of-cAMP, 8, 8-bromoadenosine-
AMP; AKAR4, A-kinase activity
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B.V. Open access under CC BY license.PDAC [8,9] the processes controlling metastasis formation have not
been fully elucidated. Invasion and migration of cancer cells are
among the processes essential for the formation of metastases [18,35].
In this studywe aimed to investigate the effect of the ubiquitous second
messenger cAMP on the migration of PDAC cells.
There are 3 primary cAMP sensors: PKA, EPAC and cAMP-activated
ion channels [7]. Recent advances in the development of molecular
probes based on ﬂuorescence resonance energy transfer allow one to
monitor intracellular cAMP concentration [33,41,43,44] and its down-
stream effects on EPAC activation [33,41] and PKA activity [12,13,45]
in living cells. This is signiﬁcant since changes in this signalling cascade
can now be directly correlated with other cellular responses important
for cell migration, e.g. actin dynamics at the leading edge of the cell and
trafﬁcking of proteins in and out of focal adhesions.
The effects of cAMP and its primary sensors on cancer cell migration
are complex and cell-type speciﬁc: gradients of cAMP and PKA activity
were shown to be necessary for migration of a number of cell types
[21,25,29,32] (recently reviewed in [20]), however the inhibition of
PKA strongly potentiated migration of mouse embryonic ﬁbroblasts
[6] and Clone A colon carcinoma cells [31]. Conversely, inhibition of
PKA inhibited migration of MDA-MB-435 breast carcinoma cells [30].
Similar ambiguity exists for another primary cAMP effector: selective
activation of EPAC inhibited the migration of PC-3 prostate carcinoma
2665A. Burdyga et al. / Biochimica et Biophysica Acta 1833 (2013) 2664–2672cells [16], MDCK-GFP-EPAC kidney epithelial cells [28] and H295 adre-
nocortical carcinoma cells [2], but potentiated migration of SK-Mel-2
melanoma cells [3]. These published studies indicate that the effects of
cAMP and its effectors on migration/invasion can be very substantial
and are variable, depending on the cell-type. The outcome of interfering
with the cAMP signalling cascade is therefore difﬁcult to predict and the
effects need to be elucidated in each individual cell type.
This project was initiated by a serendipitous observation that
increasing intracellular cAMP concentration strongly inhibited migra-
tion of PDAC cells. The study aimed to characterise this phenomenon
and determine the primary cAMP effector(s) responsible for the ob-
served inhibition; this is particularly relevant considering the reported
high level expression of EPAC1 [27] and RIα subunit of PKA [15] in
PDAC cells.
2. Materials and methods
2.1. Chemicals
Forskolin (Frsk) and 8-bromoadenosine (8Br-cAMP)were purchased
from Tocris Biosciences, UK. 8-(4-Chlorophenylthio)-2′-O-methyl-cAMP
(8pCPT), N6-benzoyl-cAMP (6Bnz-cAMP) and recently developed
EPAC inhibitor (see [1]) 3-[5-(tert.-butyl)isoxazol-3-yl]-2-[2-(3-
(chlorophenyl))hydrazono]-3-oxopropanenitrile (ESI-09) were ac-
quired from BioLog, Germany. All other chemicals were from Sigma
Aldrich, UK.
2.2. Cell culture
PDAC cell lines PANC-1, BxPC3, CAPAN-2, MiaPaca-2 (all
obtained from the American Type Culture Collection) and SUIT-2
[23], were maintained in Dulbecco's modiﬁed Eagle's medium
(DMEM), supplemented with 10% foetal bovine serum (FBS), peni-
cillin (100 units/ml), streptomycin (100 μg/ml) and L-glutamine
(0.29 mg/ml). All tissue culture reagents were purchased from
Invitrogen (Paisley, UK). Cell cultures were maintained in standard
humidiﬁed incubators (Wolf Laboratories) at 37 °C and 5% CO2. Prior to0
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Fig. 1. Increasing cAMP inhibits migration of PANC-1 cells. (A) PANC-1 cell migration, as
inhibited by 20 μM forskolin (Frsk), 1 mM IBMX and a combination of the two reagents. (B
cAMP levels in PANC-1 cells (n = 34). (C) The effect of 1 mM IBMX and a combinati
(D) PANC-1 cell migration, as measured by Boyden chamber assays (n = 9 for each condit
cAMP levels in PANC-1 cells (n = 37); 20 μM Frsk and 1 mM IBMX were added at the en
Matrigel-coated Boyden chambers (n = 6 for each condition), was inhibited by 20 μM Frskany imaging experiments, cells were washed with and transferred into
Na+-HEPES-based extracellular solution (containing 140 mM NaCl,
4.7 mM KCl, 1.13 mMMgCl2, 10 mM HEPES (pH 7.4), 10 mM glucose,
1.8 mM CaCl2).
2.3. Plasmid constructs and transfection
Cells were transfected at approximately 60% conﬂuency using
PromoFectin reagent (PromoKine, UK), according to manufacturer's
instructions.
EPAC based cAMP FRET sensor CFP(nd)-EPAC(dDEP/CD)-Venus(d)
(H84; see http://research.nki.nl/jalinklab/Constructs.htm and [41]),
was produced in the laboratory of Dr. K. Jalink (The Netherlands Cancer
Institute). The effects of different concentrations of Frsk (adenylyl cy-
clase activator), IBMX (phosphodiesterase inhibitor) and membrane
permeable cAMP analogues were tested in preliminary experiments
on PANC-1 cells expressing H84. For example, we observed that 1 mM
IBMX produced stronger H84 responses than 0.1 mM IBMX but further
increase of IBMX concentration did not signiﬁcantly increase the H84
response relative to 1 mM (Fig. S1). The concentrations of the individu-
al compounds that produced clearly resolvable (but not saturating)
responses of H84 were selected for further studies of the role of cAMP
in PANC-1 cell migration (not shown). PKA sensor (AKAR4, containing
PKA substrate sequence and Cerulean–Venus FRET pair) [12,13] was
produced in the laboratory of Dr. J. Zhang (The Johns Hopkins
University School of Medicine). PKA based cAMP FRET sensor
(RII-L20-CFP + CAT-YFP) [26] was a gift from Dr. M. Zaccolo (Universi-
ty of Oxford). PKI-mCherry [39]was a gift fromDr.M. Ginsberg (Univer-
sity of California, San Diego). Paxillin–GFP was obtained from Addgene
(Addgene plasmid 15233, PI Alan Horwitz [24]). Vinculin-Venus was
from Addgene (Addgene plasmid 27300, Martin Schwartz, [17]).
LifeAct-GFP was from Ibidi (Martinsried, Germany).
2.4. Confocal microscopy and FRET imaging
Leica AOBS TCS SP2 inverted laser scanning confocal microscope
(LSCM)was used for cell imaging. Imaging experimentswere conducted2700 3600
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Fig. 2. Treatment with forskolin and IBMX inhibits rufﬂe formation in PANC-1 cells. (A) Effect of 20 μM forskolin (Frsk) and 1 mM IBMX on rufﬂing and actin dynamics in lamellipodium of a
PANC-1 cell. (A1) Transmitted light images of the cell before, during and after the treatment with Frsk and IBMX. The changes of rufﬂing and actin dynamics shown in (A3) and (A4) were
measured along the line drawn across the plasma membrane region (shown in A1 and A2). Scale bar represents 10 μM. (A2) The ﬂuorescence images of LifeAct-GFP expressed in the same
cell. (A3) The rufﬂe formation plot (a kymograph) shows transmitted light intensity measured along the line drawn across the plasma membrane region (shown in A1) and plotted against
time. Note the disappearance of rufﬂes following treatment with Frsk and IBMX. Removal of Frsk and IBMX from the extracellular solution restored the rufﬂing. (A4) The ﬂuorescence of
LifeAct-GFP measured in the same cell along the line drawn across the plasma membrane region (shown in A2; the location of the line is the same as in A1) and plotted against time. (B)
Correlation between cAMP levels and rufﬂe formation. (B1) The kymograph shown in the lower part of the ﬁgure was constructed using the same procedure as illustrated in part A of this
ﬁgure. Rufﬂe dynamics were monitored simultaneously with cAMP measurements (using H84) and displayed against the same time points as cAMP measurements (n = 3). (B2) Shows
a fragment of recordings displayed in B1 on expanded time scale. Note the correlation between the cAMP increase induced by 20 μM Frsk and 1 mM IBMX and the cessation of rufﬂing.
Fig. 3. Increasing cAMP induces paxillin trafﬁcking out of focal adhesions and inhibits turnover of focal adhesions. (A) Inhibition of focal adhesion turnover and loss of paxillin from focal
adhesions inmigrating PANC-1 cells. (A1) Cells were transfected with paxillin–GFP and (after 1800 s control period) subjected to 20 μM forskolin (Frsk) + 1 mM IBMX (from 1800 s to
3600 s), this was followed by awash period (from 3600 s to 5400 s). Note the decrease of the number and ﬂuorescence intensity of paxillin–GFP-labelled structures during Frsk + IBMX
treatment. Scale bar represents 10 μm. (A2) The four images fromA1were thresholded using ImageJ (seeMaterials andmethods) in order to reveal focal adhesions. The two thresholded
images from the control period (0 s and 1800 s, see left panel) were assigned red and green colours respectively and merged together using ImageJ; thus newly formed focal adhesions
appear green, whilst focal adhesions which have disassembled within the 1800 s period appear red. Some focal adhesions (or parts of focal adhesions) did not change within the 1800 s
period and appear yellowas a result of the overlap between the red and green colours. The same processwas used tomerge thresholded images from1800 s to 3600 s during the period of
Frsk + IBMX application (see central panel). 1800 s image was assigned red colour this time, whilst 3600 s image was coded green. The same process was used again to merge images
recorded at 3600 s and 5400 s (i.e. taken during thewash period; see right panel). Scale bar represents 10 μm. (A3) Shows expanded fragment from A2 (outlined by a box on A2). On the
left panel green arrow shows an example of newly formed paxillin–GFP-labelled focal adhesion; red arrow shows an example of focal adhesion that disappeared during theﬁrst 1800 s of
the experiment; yellow arrow shows an example of focal adhesion that remained largely unchanged.Note the disappearance of paxillin–GFP-labelled focal adhesions during Frsk + IBMX
application (central panel; focal adhesion that disappeared during the period of the application is shown by red colour, an example of focal adhesion that was reduced in size but still
present at the end of the treatment is shown by white arrowhead). Finally, removal of Frsk + IBMX restored the formation of new focal adhesions (green-coloured structures on the
right panel). (B) Images of a stationary cell transfected with paxillin–GFP and treated with 20 μM Frsk + 1 mM IBMX. (B1) Shows reversible decrease of ﬂuorescence in focal adhesions
upon addition of Frsk + IBMX (see alsoMovie S2). Scale bar corresponds to 10 μm. (B2) Top left panel shows the same cell as in B1, with the outlined region shown as an expanded frag-
ment on the lower left panel. Lower left panel shows the fragment with the highlighted regions of interest (containing focal adhesions) selected for analysis. The ﬂuorescence recorded
from individual regions of interests each containing a single focal adhesion (FFa, shown in the left panel) was divided by ﬂuorescence recorded from regions of the cell devoid of focal
adhesions (FC) and plotted against time. Colours of the traces in the right panel correspond to the colours of the outlines of the regions of interest shown in the left panel. (C) Correlation
between cAMP levels and paxillin trafﬁcking in PANC-1 cells. (C1) Images of the cell transfected with paxillin–PSmOrange. Note the decrease of ﬂuorescence in focal adhesions upon ad-
dition of 20 μM forskolin (Frsk) and 1 mM IBMX. Scale bar corresponds to 10 μm. (C2) Top left panel shows the same cell as in C1, with the outlined region shown as an expanded frag-
ment on the lower left panel. Lower left panel shows the fragment with the highlighted region of interest (containing single focal adhesion) selected for analysis. The ﬂuorescence
recorded from the region containing the focal adhesion (FFa) was divided by ﬂuorescence recorded from the region of the cell devoid of focal adhesions (FC) and plotted against time
(green line). The cAMP levels (H84 response) were measured from the entire cell and displayed against the time on the same graph (black line).
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2668 A. Burdyga et al. / Biochimica et Biophysica Acta 1833 (2013) 2664–2672at 35–37 °C. Cells were grown to approximately 80% conﬂuency in
35 mmglass-bottom dishes (MatTek, USA), andwere placed into a cus-
tom made insert designed to accommodate the dish and allow changes
of extracellular solution by perfusion.
Fluorescence of paxillin–GFP was excited using a 488 nm laser, and
emission collected between 500 and 570 nm. In speciﬁc experiments
aimed to reveal dynamics of focal adhesions (e.g. Fig. 3A and correspond-
ing text in the Results section), all images were equally thresholded and
subjected to single pixel size “remove outliers” function using ImageJ soft-
ware to eliminate cytosolic component of ﬂuorescence and highlight the
position of focal adhesions. The dynamic turnover of the focal adhesions
was then revealed by comparing two thresholded images that were
recorded 1800 s apart: the images were merged together and structures
with ﬂuorescence above threshold on the ﬁrst image were assigned the
red colour, whilst the structures on the second image (that was taken
1800 s later) were coloured green. Therefore newly forming focal adhe-
sions appear green on such merged images, whilst focal adhesions
which have disassembled within the 1800 s period appear red. Some
focal adhesions did not change within the 1800 s period and appear yel-
low as a result of the overlap between the red and green colours.
Paxillin–PSmOrange was from Addgene (Addgene plasmid
31923, PI Vladislav Verkhusha) [38]. Notably this plasmid encodes
a photoswitchable version ofmOrange; however in all our experiments,
low intensity laser light was used to ensure that no photoswitching
occurred and thus the probe was used as an ordinary mOrange tag
with its typical excitation and emission spectra. PSmOrange was excited
by a 543 nm laser and emission collected between 560 and 670 nm.
PKI-mCherry was excited using a 594 nm laser line, and emission
collected between 605 and 690 nm.
Vinculin-Venus was excited using a 514 nm laser line and emission
was collected between 530 nm and 590 nm.
LifeAct-GFPwas excited using a 488 nm laser, and emission collected
between 500 and 570 nm.
All FRET sensors utilised CFP (or Cerulean) and YFP (or Venus). In all
experiments with FRET sensors a 405 nm laser linewas used for excita-
tion of ﬂuorescence; ﬂuorescence emission was collected for CFP or Ce-
rulean between 450 and 490 nm, whilst for YFP or Venus it was
between 520 and 590 nm. The ratio of ﬂuorescence recorded using
these wavelength bands was normalised to the baseline ratio and plot-
ted against time to illustrate changes of cAMP levels or responses of its
effectors. Quantiﬁcation of recorded time-series images was performed
using Leica Application Suite AF Lite software and ImageJ software.
The n numbers indicated in the Results section or ﬁgure legends
are the number of individual cells in each experimental condition.
Each type of experiment was repeated using at least 3 separate cell
preparations.
2.5. Migration and invasion assays
Cell migration was assessed using 24-well Boyden chambers with
8 μM pore size (BD Biosciences, UK), and were used as speciﬁed by
the manufacturer. DMEM supplemented with 1% FBS was placed
into the top and bottom well of the Boyden chamber. Cells seeded
into the top well were allowed to migrate through the porous mem-
brane for 6 h in the incubator at 37 °C and 5% CO2. To test cell invasion,
Matrigel covered Boyden chambers (BD Biosciences, UK), were used ac-
cording tomanufacturer speciﬁcation. Cell migration and invasionwere
also assessed in conditions of asymmetric FBS distribution; in these ex-
periments, bottom wells were ﬁlled with DMEM supplemented with
10% FBS, and the top wells with DMEM alone (i.e. no FBS added). Fol-
lowing 6 h of incubation, Boyden chambers were ﬁxed using 100%
methanol for 10 min at room temperature. Non-migrated cells were
scraped away from the top surface of the Boyden chamber membrane.
Boyden chambers were then placed into phosphate buffered solution
(PBS), containing 137 mM NaCl, 2.68 mM KCl, 10.1 mM Na2HPO4, and
1.76 mM KH2PO4, and pH adjusted to 7.4 supplemented with 10 μg/mlRNase A for 30 min, whichwas followed by treatmentwith PBS solution
supplemented with 100 μg/ml propidium iodide for 10 min at room
temperature. Any remaining non-migrated cells were removed from
the top surface of the membrane for a second time and the chambers
werewashed twice using PBS. The chamberswere then placed into indi-
vidual wells of 24-well plates containing 1 ml PBS per well and imaged
using a 10× objective and the Leica AOBS TCS SP2 confocal microscope.
CellProﬁler software [5] was used to identify and count the stained cells
on the lower surface of the membrane. The n numbers indicated in the
Results section or ﬁgure legends are the number of individual Boyden
chambers for each experimental condition. Each type of experiment
was repeated using at least 3 separate cell preparations. The results
were analysed using Student's t-test, andp b 0.05was considered statis-
tically signiﬁcant (and indicated by the symbol * on the ﬁgures). For
each of the tested compounds the number of migrated cells was
normalised to that in the control (untreated cells with appropriate vehi-
cle) and presented as percentage of control. In data presentation the
error margins represent standard error of mean.
2.6. Analysis of rufﬂing
A macro developed by Deming and colleagues [11] was used in
conjunction with ImageJ software [36] to processes transmitted
light series of images, reveal the rufﬂing and minimise background
intensity ﬂuctuation induced by the perfusion system. Processed
image series were then used to produce kymographs from selected
lines of interest, using the ImageJ plug-in ‘Multiple Kymograph’ de-
veloped by Jens Rietdorf and Arne Seitz (http://www.embl.de/
eamnet/html/body_kymograph.html).
3. Results
3.1. Elevated cAMP inhibits PDAC cell migration and invasion
We observed that interventions increasing intracellular cAMP levels,
such as treatment of cells with Frsk or IBMX, signiﬁcantly inhibited
PANC-1 cell migration as measured by Boyden chamber assays
(Fig. 1A–C). Combined treatment with Frsk and IBMX produced stronger
increases of cAMP (Fig. 1B and C) and stronger inhibition of migration
(up to 95%) than the individual substances alone (Fig. 1A). Increasing in-
tracellular cAMP with Frsk and IBMX also strongly inhibited the migra-
tion of SUIT-2, CAPAN-2, BxPC3 and MiaPaca-2 cell lines (Fig. S2).
The membrane-permeable cAMP analogue, 8Br-cAMP- also
inhibited PANC-1 cellmigration, conﬁrming that the observed inhibition
of migration is likely to be cAMP-mediated (Fig. 1D). The strength of the
inhibition correlated with the response of the cAMP sensor (Fig. 1A-E).
Interestingly, high concentrations of 8Br-cAMP were necessary to pro-
duce the inhibition of migration and to induce signiﬁcant ﬂuorescence
changes in the cAMP sensor (see Fig. 1E). This could be due to the rela-
tively low permeability of this analogue (see http://www.biolog.de/
technical-info/lipophilicity-data/). Another contributing factor could be
the high activity of phosphodiesterases in this cell type.
Increasing intracellular cAMP with Frsk and IBMX strongly
suppressed PANC-1 cell invasion (Fig. 1F). Migration and invasion in
conditions of asymmetrical FBS distribution were also strongly
inhibited (Fig. S3). The results of these experiments are consistent
with the reports of cAMP-mediated inhibition of migration in other
cancer cell types (e.g. [2,7]), but note that some studies (e.g. [30]) re-
port duality in the actions of cAMP i.e. cAMP can be required for mi-
gration or inhibit migration (depending on the mechanism of its
generation; recently reviewed in [20]).
3.2. The effect of cAMP on rufﬂes
Rufﬂing is a process closely associated with cell migration [11]. In our
experiments cAMP increases exerted powerful and rapid effects on
2669A. Burdyga et al. / Biochimica et Biophysica Acta 1833 (2013) 2664–2672integral components of the migratory machinery. The addition of Frsk
and IBMX resulted in a decrease of actin density at the leading edge of
the cell and cessation of rufﬂing (Fig. 2A andMovie S1, n = 6 for cells ex-
pressing LifeAct-GFP). The inhibition of rufﬂing by Frsk and IBMX was
also recorded in more than 50 untransfected PANC-1 cells (not shown).
Simultaneous measurements of cAMP and visualisation of rufﬂes using
a kymograph approach showed that rufﬂing is very effectively and rapid-
ly inhibited following cAMP increase (importantly, rufﬂing stopped be-
fore the cAMP probe was saturated) and recovered completely
following the return of the cAMP concentration to resting levels
(Fig. 2B, n = 3 for simultaneous measurements of cAMP and rufﬂing).Pa
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Fig. 4.Modulating PKA activity affects migration, rufﬂing and paxillin trafﬁcking in PANC-1 c
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recorded from the region of the cell devoid of focal adhesions (FC). Frsk + IBMX represen
the left represent measurements taken from cells expressing paxillin–GFP (n = 23); t
PKI-mCherry (n = 29). (E) Expression of PKI-mCherry partially prevents the inhibition of m
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all conditions, the protective effect of PKI-mCherry expression was statistically signiﬁcant).3.3. The effect of cAMP on focal adhesion turnover and paxillin
localisation
Turnover of focal adhesions is important for migration [22]. In our
experiments focal adhesions were revealed using ﬂuorescently-
labelled paxillin (Fig. 3). In migratory cells that continuously formed
new focal adhesions before application of Frsk and IBMX, treatment
with Frsk and IBMX stopped the formation of new focal adhesions
(Fig. 3A, n = 5). In these experiments we observed apparent loss of
focal adhesions and/or signiﬁcant decrease of paxillin content of focal
adhesions upon Frsk and IBMX treatment (Fig. 3A). Removal of Frsk1.0
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ells. (A) Shows PKA activation measured using AKAR4. The PKA activation was induced
ivation. The black trace shows the response of AKAR4 (i.e. changes of PKA activity) in-
i.e. cells that are not transfected with PKI-mCherry, n = 46). The red trace (displaying
0 μM Frsk or (crucially) by the combination of 20 μM Frsk and 1 mM IBMX, is blocked
Frsk and 1 mM IBMX. The ﬁgure contains kymographs illustrating rufﬂing of a cell
ontinued to rufﬂe in the presence of Frsk and IBMX) and of an untransfected control
ssion of PKI-mCherry partially inhibits the trafﬁcking of paxillin out of focal adhesions
ded from regions of interests containing focal adhesions (FFa) divided by ﬂuorescence
t measurements taken after 30 min of treatment with these compounds. The bars on
he bars on the right (shown in red) represent cells expressing paxillin–GFP and
igration induced by 20 μM Frsk and 1 mM IBMX. Migration was measured by Boyden
the bars on the right (shown in red) represent cells expressing PKI-mCherry (n = 6 for
2670 A. Burdyga et al. / Biochimica et Biophysica Acta 1833 (2013) 2664–2672and IBMX restored turnover of focal adhesions and increased concen-
tration of paxillin–GFP in focal adhesions (Fig. 3A).
In non-migratory or slowmoving cells the focal adhesions were rel-
atively stable. These cells allowed us to visualise rapid and reversible
trafﬁcking of paxillin out of focal adhesions induced by application of
Frsk and IBMX (Fig. 3B and Movie S2, n N 30). Simultaneous imaging
of paxillin–GFP and measurement of cytosolic cAMP (n = 4) showed
clear correlation between the two processes: the loss of paxillin from
focal adhesions following the cAMP increase (Fig. 3C and Fig. S4) and
the return of paxillin to the focal adhesions following the recovery of
cAMP concentrations (Fig. S4).
Inhibition of the turnover of focal adhesions was also revealed in
PANC-1 cells expressing ﬂuorescently-labelled vinculin (Fig. S5).
The rapidity of these responses suggested that the cAMP-induced
inhibition of migration and invasion of PDAC cells are likely to bemedi-
ated by direct action of cAMP effector(s) on the migratory apparatus of
the cells (rather than via cAMP-dependent changes in gene expression).
PKA and EPAC are two prominent cAMP effectors. Therefore we next
tested their roles in cAMP-induced inhibition of cell migration.
3.4. The effects of cAMP on rufﬂes, focal adhesions and cell migration are
likely to be mediated by PKA
As expected, PKA activity (measuredwith AKAR4) increased rapidly
following Frsk and IBMX addition (Fig. 4A, n = 9). Expression of
PKI-mCherry is, to our knowledge, the most speciﬁc way of inhibiting
PKA activity; in our experiments the expression of PKI-mCherry
completely inhibited PKA activation by Frsk and by a combination of
Frsk and IBMX (Fig. 4B). PKI-mCherry expression also effectively
prevented Frsk and IBMX-induced cessation of rufﬂing (Fig. 4C) and
partially prevented paxillin trafﬁcking from focal adhesions (Fig. 4D).
Importantly, expression of PKI-mCherry signiﬁcantly (albeit0 900 1800 2700 3600
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Fig. 5. Effects of selective activators of EPAC and PKA on the migration of PANC-1 cells. (A
8-(4-chlorophenylthio)-2′-O-methyl-cAMP (8pCPT, n = 30). Here and in (B), (D), and (E)
to saturate the FRET probes. (B) FRET of AKAR4 (PKA activity reporter) did not change up
chamber assays, was signiﬁcantly potentiated by 300 μM 8pCPT (n = 16 for both control
concentrations (10 μM and 30 μM) of 8pCPT (see Fig. S7). (D) Response of AKAR4 to the a
sensor H84 did not change upon the application of 6 mM 6Bnz-cAMP (n = 29). (F) Migrat
by 6 mM 6Bnz-cAMP (n = 7).incompletely) blocked the inhibition of migration in response to Frsk
and IBMX (Fig. 4E). It should also be noted that expression of
PKI-mCherry alone has a tendency to potentiate migration of PANC-1
cells but in this case the effect was not statistically signiﬁcant (n = 6).
The effects of PKI-mCherry expression suggest that cAMP actions
on rufﬂing, paxillin trafﬁcking andmigration are likely to be mediated
by PKA. It was, however, important to test the role of another cAMP
effector, EPAC.
The selective activator of EPAC 8pCPT [14] applied at 300 μM had a
strong (albeit not saturating) effect on the EPAC-based FRET sensor
(Fig. 5A) and had no resolvable effect on PKA activity (Fig. 5B). Impor-
tantly this selective EPAC activator moderately potentiated rather
than inhibited PANC-1 cell migration (Fig. 5C) and had no resolvable
effect on rufﬂing or paxillin trafﬁcking (n = 10 and n = 11 corre-
spondingly). Consistent with this result the inhibition of EPAC with re-
cently developed inhibitor ESI-09, suppressedmigration of PANC-1 cells
(Fig. S8A, n = 6). Furthermore, the application of ESI-09 did not reduce
the inhibition of migration by Frsk and IBMX (Fig. S8B, n = 6); this
clearly contrasts with the effect of PKA inhibitor.
The novel ﬁnding (acceleration of migration by EPAC activator)
observed in our experiments in PDAC cells is consistent with the
reported potentiating action of EPAC on the migration/invasion of a
melanoma cell line [3]. Importantly, the observed potentiation of
migration supports the conclusion, based on experiments with a
recently identiﬁed inhibitor of EPAC [1], that EPAC (and speciﬁcally
EPAC1) is important for migration of PDAC cells and that EPAC inhibi-
tion suppresses migration.
On the contrary, the selective PKA activator N6-benzoyl-cAMP
(6Bnz-cAMP) induced PKA responses (Fig. 5D and Fig. S6), had no
resolvable effect on the EPAC-based sensor (Fig. 5E) and suppressed
cell migration (Fig. 5F). These experiments indicate that EPAC and
PKA have opposing effects on the migration of PANC-1 cells and0
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) Response of the EPAC-based FRET sensor H84 expressed in PANC-1 cells to 300 μM
20 μM forskolin (Frsk) and 1 mM IBMX were applied at the end of the experiments
on the application of 300 μM 8pCPT (n = 21). (C) Migration, measured using Boyden
and 8pCPT treated cells). Note that migration was not signiﬁcantly modiﬁed by lower
pplication of 6 mM N6-benzoyl-cAMP (6Bnz-cAMP, n = 28). (E) FRET of EPAC-based
ion of PANC-1 cells measured using Boyden chamber assays was signiﬁcantly inhibited
2671A. Burdyga et al. / Biochimica et Biophysica Acta 1833 (2013) 2664–2672that the inhibitory effect of cAMP on PANC-1 cell migration is likely to
be mediated by PKA.4. Discussion
Understanding the mechanisms regulating migration of PDAC
cells is important for elucidating the processes leading to metastasis
formation in this lethal form of cancer. We investigated the role of
cAMP signalling in the regulation of migration and observed that
increasing cAMP concentration resulted in the inhibition of migration
of all tested PDAC cell lines. Previous studies have shown that the effect
of cAMP onmigration of cancer cells is ambivalent—migration of some
cell types is inhibited by cAMP increase whilst other cell types require
cAMP signalling for efﬁcient migration (reviewed in [19,20]). In this
study we have tested a number of PDAC cells lines which have diverse
genetic background and origin [10], however, all these PDAC cell lines
displayed inhibition of migration as a result of cAMP elevation,
suggesting that this phenomenon is common for different populations
of cancer cells derived from this type of cancer. The observation that
an increase of cAMP strongly inhibits migration of PANC-1 and other
PDAC cell types suggests that this phenomenon could be exploited to
develop treatments capable of delaying the progression of PDAC.
An important element of this study is that we extensively utilised
an EPAC-based cAMP sensor (H84) [41] and a PKA sensor (AKAR4)
[12,13] to correlate the cAMP levels and the status of its effectors
with the observed changes in migration, rufﬂing, focal adhesions
and paxillin trafﬁcking. These measurements revealed that different
manoeuvres, which increase cAMP (inhibition of phosphodiesterases,
stimulation of adenylate cyclases or application of membrane
permeant cAMP analogues) all resulted in the inhibition of migration
and that the inhibition of migration depended on the amplitude of
cAMP increase. The simultaneous measurements of cAMP levels and
visualisation of membrane rufﬂing highlighted synchronicity of the
cAMP elevation and the inhibition of rufﬂing, and indicated that the
inhibition develops well before the saturation of the cAMP sensor.
We also observed remarkable synchronicity of cAMP rise and paxillin
trafﬁcking out of focal adhesions. Such observations certainly reafﬁrm
the causative relationships between the cAMP increase and modiﬁca-
tion of cellular migratory apparatus. Measurements utilising H84 and
AKAR4 provided strong evidence that the cAMP analogue, expected to
be EPAC selective, indeed activated EPAC and did not activate PKA and
vice versa for PKA selective cAMP analogue. Finally, remarkably efﬁcient
inhibition of PKA responses by expressed PKI was conﬁrmed by exper-
iments with cells expressing AKAR4. It should be noted, however, that
whilst PKI effectively inhibits global PKA responses (reported by
AKAR4) some form of localised PKA signalling could still be maintained
and contribute to the partial inhibition of migration in Frsk and IBMX
treated cells expressing PKI.
The ﬁndings of our study show that the cAMP-induced inhibition
of migration of PDAC cells is mediated by PKA and that the activation
of EPAC has an opposing action.
These observations suggest that the development/optimisation of a
treatment protocol involving simultaneous inhibition of EPAC and acti-
vation of PKA could be necessary to effectively inhibit PDAC cell migra-
tion in vivo and ultimately suppress the formation of metastases.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.06.011.Sources of funding
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